Compare Regeneron Pharmaceuticals Inc (REGN) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Tencent Music Entertainment Group - ADR — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Tencent Music Entertainment Group - ADR trades at $8.76 (market cap $15.16B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.7× Tencent Music Entertainment Group - ADR's market cap, and Tencent Music Entertainment Group - ADR pays the higher dividend (2.68%). Which is the better fit depends on your goals.
| REGN | TME | |
|---|---|---|
Market Cap | $70.79B | $15.16B |
Sector | Health | Media |
52-Week High | $812.27 | $26.36 |
52-Week Low | $545.46 | $8.16 |
Enterprise Value | $64.74B | $11.93B |
Dividend Yield | 0.56% | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
TME trades at $8.94, down 1.97% for the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong 2025 revenue of $32.90B and net income of $11.06B, with a net income margin of 26.48%. Recent news highlights strategic moves like the Ximalaya acquisition and a partnership with Coca-Cola for the 2026 FIFA World Cup anthem.
The outlook is mixed; analyst consensus is a 'Hold' with a $14.00 price target, implying significant upside. Key opportunities include premium membership growth and ecosystem integration, while risks involve competition, user churn, and AI-related copyright issues. Cash flow trends show a projected recovery in 2026 after a negative 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
